---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-029012"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-09-12T23:59:59+00:00"
generated_at: "2026-05-31T05:14:40.648425+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Monopar reports positive early human data for MNPR-101-Zr tumor targeting

## Summary
- MNPR-101-Zr PET image at 168h post-dose in first cancer patient shows high preferential uptake in metastatic tumors.
- Uptake aligns with FDG-PET locations; imaging performed on high-sensitivity Siemens Biograph Vision Quadra scanner.
- Company aims to launch MNPR-101-Lu Phase 1 therapeutic trial in Q4 2024.
- Additional data to be presented at EANM 2024 Congress (Oct 19-23) as 'Top-Rated Oral Presentation'.
- MNPR-101 targets uPAR, expressed in majority of triple-negative breast, colorectal, bladder, ovarian, gastric, and pancreatic cancers.

## SEC filing metadata
- accession: 0001437749-24-029012
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924029012/0001437749-24-029012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924029012/mnpr20240911_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-029012
- JSON: https://secwatch.observer/filing/0001437749-24-029012.json
- Plain text: https://secwatch.observer/filing/0001437749-24-029012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.